Previous Article | Next Article ![]()
Molecular and Cellular Biology, September 2002, p. 6553-6563, Vol. 22, No. 18
0270-7306/02/$04.00+0 DOI: 10.1128/MCB.22.18.6553-6563.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.
Laboratory of Viral Carcinogenesis, Cancer Research UK, London Research Institute, Lincolns Inn Fields Laboratories, London, United Kingdom WC2A 3PX
Received 28 March 2002/ Returned for modification 15 May 2002/ Accepted 7 June 2002
| ABSTRACT |
|---|
|
|
|---|
| INTRODUCTION |
|---|
|
|
|---|
The selective targeting of proteins from the trans-Golgi network (TGN) to the basolateral membrane requires the presence of cis-acting signals. For the most part, basolateral sorting or targeting signals have been identified as minimal amino acid motifs in the juxtamembrane cytoplasmic region of membrane proteins. Several cell surface receptors possess signals similar to those involved in clathrin-mediated endocytosis, which rely either on a critical tyrosine residue, as found in the low-density lipoprotein (LDL) receptor (27) and the vesicular stomatitis virus glycoprotein (35), or on a dihydrophobic motif, as found in E-cadherin (29) and the Fc receptor (16). Other basolateral sorting motifs, unrelated to clathrin-mediated endocytic signals, have been described for the neural cell adhesion molecule (N-CAM) (23), and epidermal growth factor receptor (14). The similarity between these basolateral sorting signals and clathrin-coated pit determinants has suggested that the adaptor proteins might also be implicated in basolateral sorting (reviewed in reference 26). In particular, epithelial cells deficient in the heteromeric adaptor complex AP1B or AP4 have been shown to missort several basolateral proteins to the apical membrane (10, 31, 33).
In addition to cis-acting signals, PDZ domain-containing proteins can act in trans to correctly target or to retain receptors at either the apical or basolateral domain of epithelial cells, as well as the pre- or postsynaptic membranes of neurons. These PDZ domain-containing proteins usually interact with a short amino acid sequence at the extreme C terminus of the targeted membrane protein (for reviews see references 9 and 19).
The ERBB/HER family of receptor tyrosine kinases (RTKs) consists of four members in mammals: the epidermal growth factor receptor (also called ERBB1, or HER1 for the human allele), ERBB2/HER2, ERBB3/HER3, and ERBB4/HER4. These receptors play crucial roles in animal development, and their aberrant expression has been associated with tumorigenesis (reviewed in reference 1). In epithelia, ERBB1 and ERBB2 are predominantly localized to the basolateral membrane (3, 5, 7, 13), where they are able to mediate signals between the epithelium and the adjacent mesenchyme. Although structurally homologous to other members in the family, ERBB2 is unique in that ligand-mediated homodimers have not been identified, indicating that normal signal transduction occurs through the formation of heterodimers (20). Moreover, ERBB2 seems to be the preferred heterodimerization partner for other family members (12).
Despite a high degree of homology between ERBB family members, the mechanisms that govern receptor localization appear to differ. Whereas ERBB1 has been shown to contain an autonomous basolateral sorting signal in the juxtamembrane region (13, 14), a trans-acting mechanism of localization through an interaction with the PDZ domain-containing protein ERBIN appears to control ERBB2 localization (3). We have undertaken extensive mutagenic analyses of ERBB2 to investigate the signals involved in its targeting. In this report we identify and characterize a novel bipartite juxtamembrane basolateral sorting signal that is both necessary and sufficient for the targeting of ERBB2. Moreover, we find no evidence that the C-terminal ERBIN binding domain of ERBB2 plays a role in basolateral localization. These studies extend the repertoire of basolateral sorting signals and provide further insights into the role of C-terminal PDZ protein binding domains in membrane trafficking.
| MATERIALS AND METHODS |
|---|
|
|
|---|
DNA plasmids and mutagenesis.
A 4-kb fragment of cDNA encoding the entire human ERBB2 sequence was excised from vector pSV2ERBB2 (a kind gift from Helen Hurst) (36) by digestion with HindIII and cloned into pcDNA4/TO (Invitrogen) to form plasmid pc4-B2. Four ERBB2 truncation mutants,
690,
695,
701, and
706, were generated by creating sequential C-terminal truncations at amino acids 690, 695, 701, and 706, respectively (numbering based on reference 6). PCR products were generated with a 5' HindIII site and a 3' stop codon followed by an XbaI site and cloned into pcDNA4/TO. Internal deletion mutants
684-690,
684-695,
684-706,
696-701, and
702-706 were created by deleting the indicated amino acids using a modified version of a PCR-based strategy (28). These deletions were generated by using full-length ERBB2 cDNA as a template and were then cloned by use of HindIII into pcDNA4/TO. Mutations V1255A and
1249 contain a valine-to-alanine mutation at position 1255 and a deletion of the last 6 C-terminal amino acids, respectively. Mutations were generated by using a forward primer annealing to sequences 5' of the Eco47III site and a reverse mutagenic primer containing the appropriate mutation, followed by a 3' stop codon and an XbaI site. Mutated ERBB2 fragments were then cloned into pc4-B2 by using Eco47III and XbaI. All other alanine mutations were generated with the QuikChange XL site-directed mutagenesis kit (Stratagene) using pc4-B2 as a template.
Chimeric P75 neurotrophin receptor (P75NTR)/ERBB2 receptors were created by generating a truncated P75NTR product with a HindIII site 5' to the initiation codon and an in-frame EcoRV site at position 930 (numbering based on reference 18). This was cloned into pcDNA4/TO by using HindIII/EcoRV to generate plasmid pP75-TrFu. A similar vector containing a double stop codon 5' to the EcoRV site (pP75-Tr) was constructed. EcoRV/NotI digestion allowed the ligation of ERBB2 fragments corresponding to amino acids 680 to 690 [P75B2(680-690)], 680 to 706 [P75B2(680-706)], 1241 to 1255 [P75B2(C15)], and 680 to 1255 [P75B2(680-1255)] into pP75-TrFu. Two further chimeric receptors based on P75B2(C15) were generated by mutating the C-terminal valine [P75B2(C15)VA] or tyrosine [P75B2(C15)YA] to an alanine residue. All ERBB2 mutants and chimeric receptor constructs were verified by DNA sequencing.
µ1B was amplified from reverse-transcribed cDNA obtained from MCF10A cells, verified by DNA sequencing, and subsequently cloned into pcDNA3 (Invitrogen) by using HindIII and NotI. A transferrin receptor (TFr) expression vector was kindly provided by Colin Hopkins (Imperial College, London, United Kingdom).
Cell culture. Madin-Darby canine kidney (MDCK) and LLC-PK1 (American Type Culture Collection) cells were grown and passaged in Dulbecco's modified Eagle's medium (DMEM) (Cancer Research UK Cell Services) supplemented with 10% fetal bovine serum (Gibco-BRL) and maintained under 10% CO2 at 37°C. Cells were transfected by using Lipofectamine reagent (Invitrogen) according to the manufacturer's instructions. Stable cell lines were generated by cotransfecting an FspI-linearized expression plasmid and pcDNA6/TR (Invitrogen) at a ratio of 1:5. Individual clones were selected, maintained in medium as above supplemented with Zeocin (400 µg/ml) and blasticidin S HCl (5 µg/ml) (Invitrogen), and screened for tetracycline-inducible expression by immunoblotting.
Immunoblotting. Stable cell clones grown to subconfluence in 6-well plates were induced overnight with tetracycline (1 µg/ml) (Invitrogen), washed twice with phosphate-buffered saline (PBS), and harvested using Laemmli buffer. Cell lysates were separated by electrophoresis through SDS-8% polyacrylamide gels and transferred to Protran nitrocellulose membranes (Schleicher & Schuell) using a Bio-Rad Trans-blot transfer cell. After being blocked in 5% fat-free milk powder in PBS containing 0.1% Tween 20, membranes were probed with anti-ERBB2 clone 42 (1:2,500). Bound antibodies were revealed with HRP-conjugated goat anti-mouse IgGs (1:5,000) by using the ECL detection system (Amersham).
Indirect immunofluorescence. Stable or transiently transfected cells were grown on 0.4-µm-pore size polyethylene tetraphthalate (PET) track-etched membrane cell culture inserts (Falcon) to establish a polarized monolayer. If appropriate, the cells were induced overnight with tetracycline (1 µg/ml). MDCK cells were fixed in -20°C methanol for 5 to 10 min and blocked in 0.2% fish gelatin (Sigma) in PBS for 1 h. LLC-PK1 cells were fixed in 4% paraformaldehyde in PBS and were blocked and permeabilized in PBS containing 3% bovine serum albumin (BSA) and 0.2% Triton X-100. Double immunofluorescent labeling was achieved by first incubating cells with either anti-ERBB2 9G6.10 (1:200), anti-P75NTR ME20.4 (1:1,000), anti-transferrin receptor B325 (1:100), or anti-ß-catenin (1:1,000) and anti-ZO1 (1:1,000) for 1 h and then incubating them with FITC-conjugated goat anti-mouse IgG (1:100) and TRITC-conjugated goat anti-rat IgG (1:100) for 1 h. Then cells were mounted on glass slides in Mowiol (Calbiochem) containing 2.5% 1,4-diazabicyclo[2,2,2]octane (DABCO) (Sigma). Indirect immunofluorescence was visualized by using a Zeiss LSM510 laser scanning confocal microscope.
Quantification of cell surface ERBB2. MDCK cell clones were grown to confluence on membranes as described above, induced overnight with 1 µg of tetracycline/ml, and then washed twice in cold PBS containing 0.1 mM CaCl2 and 1 mM MgCl2 (PBS++). Surface biotinylation of apical or basolateral proteins was performed twice at 4°C for 20 min by using freshly prepared 0.5-mg/ml EZ-Link Sulfo-NHS-Biotin (Pierce) in PBS++. Reactions were quenched by using 50 mM NH4Cl. After several washes, cells were lysed in 1% Triton X-100-20 mM Tris-HCl (pH 8.0)-50 mM NaCl-5 mM EDTA-0.2% BSA containing a cocktail of protease inhibitors and were then cleared by centrifugation at 16,000 x g. Labeled proteins were precipitated by using immobilized streptavidin (Pierce) and were prepared for SDS-polyacrylamide gel electrophoresis (PAGE). Bound antigens were revealed with anti-ERBB2 clone 42 (1:2,500) and IR-labeled goat anti-mouse IgG (1:2,000) and were visualized and quantified by using an Odyssey IR scanner (LI COR Biosciences).
| RESULTS |
|---|
|
|
|---|
|
An assessment of the distribution of the receptor between basolateral and apical membranes was obtained by immunoblotting of biotinylated basolateral or apical membrane proteins after their selection on streptavidin beads (Fig. 2) (see Materials and Methods). The results show that full-length ERBB2 and the truncated proteins
701 and
706 were located predominantly on the basolateral membrane, while the
690 and
695 proteins were predominantly apical. However, the
695 protein also showed a small degree of basolateral expression, which is consistent with a partially compromised basolateral targeting signal. These findings are in agreement with the immunofluorescence results (Fig. 1E). Taken together, these data demonstrate the presence of a signal for basolateral sorting in the juxtamembrane region of ERBB2 between amino acids 690 and 706.
|
684-690 and
702-706) were shown to localize to the basolateral membrane similarly to the full-length receptor (Fig. 3B). By contrast, the deletion of amino acids 684 to 695 or 684 to 706 resulted in an apical location, although the larger deletion also showed a very significant punctate distribution in the cytoplasm, suggesting a perturbation of endosomal trafficking. A deletion encompassing amino acids 696 to 701 resulted in a shared apical-basolateral localization (Fig. 3B). These results establish the presence of a signal between amino acids 690 to 701 (LLQETELVEPLT) that is necessary for ERBB2 basolateral delivery even in the presence of the C-terminal PDZ protein binding domain.
|
|
|
The ERBB2 juxtamembrane targeting motif is a dominant basolateral sorting signal. To determine whether the ERBB2 juxtamembrane sequence could act as a dominant basolateral targeting signal, its ability to direct a heterologous protein to the basolateral membrane was examined. P75NTR is normally directed to the apical membrane when it is expressed in MDCK cells. Delivery of P75NTR to the apical membrane was previously shown to involve O-glycosylation sites in the stalk domain of the receptor (4, 37). P75NTR/ERBB2 chimeric receptors were generated by fusing the extracellular and transmembrane domains of P75NTR to either the complete cytoplasmic domain of ERBB2 [P75B2(680-1255)] or the cytoplasmic region of ERBB2 truncated at position 690 [P75B2(680-690)] or position 706 [P75B2(680-706)] (Fig. 6A). Stable MDCK cell clones expressing inducible forms of the chimeric receptors were selected, and their subcellular distribution was analyzed. Chimeric receptors of the predicted sizes were expressed as determined by immunoblot analysis using an antibody directed against the extracellular domain of P75NTR.
|
Missorting of ERBB2 in LLC-PK1 cells.
The AP1B complex associated with clathrin-coated vesicles has been implicated in the trafficking of proteins from the TGN to the endocytic compartment, as well as in the targeting of membrane proteins with a tyrosine-containing basolateral sorting signal (2, 10). The LLC-PK1 cell line has been shown to be deficient in the µ1B subunit of the AP1B adaptor complex and missorts basolateral proteins containing a tyrosine-based sorting motif (31). Although the ERBB2 juxtamembrane basolateral sorting signal does not contain a tyrosine, we examined its distribution in LLC-PK1 cells. Surprisingly, significant amounts of full-length ERBB2 were missorted to the apical membrane in this cell line, although the apical localization was not as complete as that of the truncation mutant
690 lacking the basolateral targeting signal (Fig. 7A). These results suggest that µ1B might bind other types of basolateral sorting motifs in addition to those containing a tyrosine or, alternatively, that LLC-PK1 cells may possess other deficiencies in protein trafficking.
|
Basolateral localization of ERBB2 is independent of the C-terminal PDZ binding domain.
The presence of the ERBB2 juxtamembrane sorting sequence presents an interesting conundrum concerning the role of ERBIN in ERBB2 basolateral targeting. In the experiments described by Borg et al. (3), either loss of the last 6 C-terminal amino acids or a valine-to-alanine C-terminal substitution was sufficient to redirect a chimeric receptor composed of ERBB1 and ERBB2 from the basolateral to the apical membranes of polarized MDCK cells. These mutations correlated with the loss of binding for a PDZ domain-containing protein designated ERBIN, suggesting that ERBIN is responsible for the basolateral targeting of ERBB2. In an attempt to resolve this paradox, we created the same mutations within ERBB2 and analyzed the subcellular localizations of the mutants. In contrast to the findings of Borg et al., the mutant ERBB2 proteins, either minus the last 6 C-terminal amino acids (
1249) or with a C-terminal V-to-A substitution at position 1255 (V1255A), showed a basolateral localization that was indistinguishable from that of full-length ERBB2 (compare Fig. 1A and Fig. 8B). These results suggest that ERBIN is not necessary for the selective targeting of ERBB2 to the basolateral membranes of MDCK cells. More recently, Jaulin-Bastard et al. (17) demonstrated that the last 15 C-terminal amino acids of ERBB2 (containing the ERBIN binding site) were sufficient to redirect a heterologous protein from the apical to the basolateral membrane. Given the contradictory results described above, we created a similar chimeric receptor consisting of the extracellular and transmembrane domains of P75NTR fused to the last 15 C-terminal amino acids of ERBB2 [P75B2(C15)]. As can be seen in Fig. 8B, the last 15 C-terminal amino acids of ERBB2 were sufficient to redirect a heterologous apically localized protein to the basolateral membrane, in agreement with the published data. However, the last 15 C-terminal amino acids of ERBB2 (PTAENPEYLGLDVPV) appear to contain two motifs that conform to the consensus sequence of tyrosine-based basolateral targeting signals (underlined), N-P-X-Y and Y-X-X-
, where
represents a hydrophobic residue. To determine whether this sequence in a juxtamembrane context might act as a targeting motif, we mutated the critical tyrosine residue to alanine [P75B2(C15)YA]. Since the tyrosine is also involved in ERBIN binding (17), we generated a second mutation that would affect ERBIN binding but is outside the putative basolateral targeting motif [P75B2(C15)VA]. The results show that the mutation of tyrosine causes a significant redirection of P75NTR to the apical membrane, whereas the mutation of the C-terminal valine gives a predominantly basolateral localization similar to that of the unmutated chimeric receptor (Fig. 8C and D). This indicates that the basolateral targeting activity of the isolated ERBIN binding site is due to a cryptic tyrosine-based basolateral targeting motif.
|
| DISCUSSION |
|---|
|
|
|---|
LLC-PK1 cells missort proteins such as the transferrin receptor and the LDL receptor that utilize a tyrosine-containing basolateral sorting signal (10). While the ERBB2 receptor is also aberrantly directed to the apical membrane in LLC-PK1 cells, interestingly, it does not contain a tyrosine in the identified sorting signal. The defect in the basolateral targeting of receptor proteins with tyrosine-containing sorting signals in LLC-PK1 cells appears to reside in the loss of the µ1B subunit of the AP1 adaptor complex, since reintroduction of a cDNA encoding the µ1B subunit rescues basolateral sorting of these receptors (10, 11, 31). Basolateral localization of ERBB2 and the transferrin receptor can be rescued by cotransfection with µ1B, although in our hands the rescue appears to be less complete than previously demonstrated for the transferrin receptor (10). Hence, the missorting of ERBB2 in LLC-PK1 cells suggests that AP1B, at least in part, may be instrumental in sorting receptors with non-tyrosine containing motifs, although this would need to be firmly established through binding studies using the adaptin heteromeric complex proteins.
Bipartite basolateral sorting motifs are not unusual. For example, the LDL receptor and the aquaporin 4 (AQP4) water channel each have a tyrosine-containing element as well as one encompassing a cluster of acidic residues (25, 27). However, while the ERBB2 sorting signal contains two or three acidic residues, they are dispersed and do not really qualify as a true acidic cluster. For example, in the LDL receptor and AQP4 water channel, 3 out of 4 key amino acid residues are acidic (25, 27). Moreover, AQP4 also has a dihydrophobic pair of amino acids adjacent to the acidic cluster that is needed for efficient basolateral sorting. A similar dihydrophobic pair of amino acids (LV) follows the two acidic residues in ERBB2 but did not appear to contribute to basolateral sorting. Furin endopeptidase also appears to contain a bipartite basolateral sorting sequence. In this case, a separate cluster of 4 acidic residues is followed by a separate phenylalanine-isoleucine pair (34). The FI pair may be equivalent to the dihydrophobic signal found in many other receptors. Therefore, it appears that the ERBB2 sorting sequence is similar to, but distinct from, those previously described.
A region of 23 amino acids in the cytoplasmic juxtamembrane of the epidermal growth factor receptor has been shown to encompass a basolateral sorting signal (14). In this study it was suggested that these amino acids might form a pair of amphipathic helices. However, the sequence we define in ERBB2 is no more than 10 amino acids long and locates on the basis of amino acid similarity only to the distal helix and the region between the two proposed helical domains of the human epidermal growth factor receptor. Nevertheless, this study, together with the results reported here, provides strong evidence for a basolateral sorting sequence in the juxtamembrane region in this family of receptors.
The extreme C-terminal region of ERBB2 contains a binding domain for the PDZ protein ERBIN, which colocalizes with ERBB2 at basolateral membranes (3). The studies of Borg et al. found that ERBIN was necessary for the basolateral localization of ERBB2, since mutations that abolished ERBIN binding also led to the mislocalization of ERBB2 to apical membranes. These findings are not consistent with the results of our experiments, since we did not find that the ERBIN binding site was necessary for basolateral targeting of the ERBB2 receptor in MDCK cells (Fig. 8). Indeed, mutation of the ERBIN binding site did not cause full-length ERBB2 to mislocalize. However, the carboxy-terminal residues of ERBB2 have a capacity to act as a basolateral targeting motif, since they were able to direct a heterologous protein to the basolateral membrane (Fig. 8).
It is not clear why our results differ from those of Borg et al., although we consider that the most likely explanation lies in their use of a chimeric receptor containing the extracellular domain of epidermal growth factor receptor fused to the cytoplasmic domain of ERBB2. It is possible that the juxtamembrane targeting signal is in some way compromised in the chimera, causing a greater emphasis to be placed on the PDZ domain. However, the internal deletion analysis presented here would not support this notion. It is also possible that basolateral sorting of these receptors could be influenced by their interaction with other proteins in the secretory pathway, such that they may provide a chaperone function. Alternatively, the persistence of ERBB2 at the basolateral membrane might be dependent on the PDZ domain acting as a retention determinant, as seen in the GABA transporter (32). Interestingly, the ability of the isolated ERBIN binding site to direct P75NTR to the basolateral membrane may rely on the presence of a cryptic sorting signal that functions when placed in a juxtamembrane position. This is strongly supported by the mutation analysis of the ERBIN binding site shown in Fig. 8. Moreover, similar tyrosine-based motifs have previously been demonstrated to act as basolateral targeting signals in the LDL receptor (NPVY) and the human immunodeficiency virus type 1 envelope glycoprotein (YSPL) (24, 27).
We conclude that the PDZ binding domain is not likely to direct basolateral sorting of ERBB2 in MDCK cells; rather, sorting is dependent on a novel bipartite juxtamembrane signal. This signal appears to be autonomous and may utilize, directly or indirectly, the AP1B adaptor complex as one means of trafficking to the cell surface.
| ACKNOWLEDGMENTS |
|---|
| FOOTNOTES |
|---|
| REFERENCES |
|---|
|
|
|---|
2. Bonifacino, J. S., and E. C. Dell'Angelica. 1999. Molecular bases for the recognition of tyrosine-based sorting signals. J. Cell Biol. 145:923-926.
3. Borg, J. P., S. Marchetto, A. Le Bivic, V. Ollendorff, F. Jaulin-Bastard, H. Saito, E. Fournier, J. Adelaide, B. Margolis, and D. Birnbaum. 2000. ERBIN: a basolateral PDZ protein that interacts with the mammalian ERBB2/HER2 receptor. Nat. Cell Biol. 2:407-414.[CrossRef][Medline]
4. Breuza, L., M. Garcia, M. H. Delgrossi, and A. Le Bivic. 2002. Role of the membrane-proximal O-glycosylation site in sorting of the human receptor for neurotrophins to the apical membrane of MDCK cells. Exp. Cell Res. 273:178-186.[CrossRef][Medline]
5. Carraway, K. L., III, and C. Sweeney. 2001. Localization and modulation of ErbB receptor tyrosine kinases. Curr. Opin. Cell Biol. 13:125-130.[CrossRef][Medline]
6. Coussens, L., T. L. Yang-Feng, Y. C. Liao, E. Chen, A. Gray, J. McGrath, P. H. Seeburg, T. A. Libermann, J. Schlessinger, U. Francke, et al. 1985. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 230:1132-1139.
7. Darcy, K. M., D. Zangani, A. L. Wohlhueter, R. Y. Huang, M. M. Vaughan, J. A. Russell, and M. M. Ip. 2000. Changes in ErbB2 (her-2/neu), ErbB3, and ErbB4 during growth, differentiation, and apoptosis of normal rat mammary epithelial cells. J. Histochem. Cytochem. 48:63-80.
8. Di Fiore, P. P., J. H. Pierce, M. H. Kraus, O. Segatto, C. R. King, and S. A. Aaronson. 1987. erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. Science 237:178-182.
9. Fanning, A. S., and J. M. Anderson. 1999. Protein modules as organizers of membrane structure. Curr. Opin. Cell Biol. 11:432-439.[CrossRef][Medline]
10. Folsch, H., H. Ohno, J. S. Bonifacino, and I. Mellman. 1999. A novel clathrin adaptor complex mediates basolateral targeting in polarized epithelial cells. Cell 99:189-198.[CrossRef][Medline]
11. Folsch, H., M. Pypaert, P. Schu, and I. Mellman. 2001. Distribution and function of AP-1 clathrin adaptor complexes in polarized epithelial cells. J. Cell Biol. 152:595-606.
12. Graus-Porta, D., R. R. Beerli, J. M. Daly, and N. E. Hynes. 1997. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J. 16:1647-1655.[CrossRef][Medline]
13. Hobert, M., and C. Carlin. 1995. Cytoplasmic juxtamembrane domain of the human EGF receptor is required for basolateral localization in MDCK cells. J. Cell. Physiol. 162:434-446.[CrossRef][Medline]
14. Hobert, M. E., S. J. Kil, M. E. Medof, and C. R. Carlin. 1997. The cytoplasmic juxtamembrane domain of the epidermal growth factor receptor contains a novel autonomous basolateral sorting determinant. J. Biol. Chem. 272:32901-32909.
15. Hogan, B. L. 1999. Morphogenesis. Cell 96:225-233.[CrossRef][Medline]
16. Hunziker, W., and C. Fumey. 1994. A di-leucine motif mediates endocytosis and basolateral sorting of macrophage IgG Fc receptors in MDCK cells. EMBO J. 13:2963-2967.[Medline]
17. Jaulin-Bastard, F., H. Saito, A. Le Bivic, V. Ollendorff, S. Marchetto, D. Birnbaum, and J. P. Borg. 2001. The ERBB2/HER2 receptor differentially interacts with ERBIN and PICK1 PSD-95/DLG/ZO-1 domain proteins. J. Biol. Chem. 276:15256-15263.
18. Johnson, D., A. Lanahan, C. R. Buck, A. Sehgal, C. Morgan, E. Mercer, M. Bothwell, and M. Chao. 1986. Expression and structure of the human NGF receptor. Cell 47:545-554.[CrossRef][Medline]
19. Kim, S. K. 1997. Polarized signaling: basolateral receptor localization in epithelial cells by PDZ-containing proteins. Curr. Opin. Cell Biol. 9:853-859.[CrossRef][Medline]
20. Klapper, L. N., S. Glathe, N. Vaisman, N. E. Hynes, G. C. Andrews, M. Sela, and Y. Yarden. 1999. The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors. Proc. Natl. Acad. Sci. USA 96:4995-5000.
21. Knust, E. 2000. Control of epithelial cell shape and polarity. Curr. Opin. Genet. Dev. 10:471-475.[CrossRef][Medline]
22. Le Bivic, A., Y. Sambuy, A. Patzak, N. Patil, M. Chao, and E. Rodriguez-Boulan. 1991. An internal deletion in the cytoplasmic tail reverses the apical localization of human NGF receptor in transfected MDCK cells. J. Cell Biol. 115:607-618.
23. Le Gall, A. H., S. K. Powell, C. A. Yeaman, and E. Rodriguez-Boulan. 1997. The neural cell adhesion molecule expresses a tyrosine-independent basolateral sorting signal. J. Biol. Chem. 272:4559-4567.
24. Lodge, R., J. P. Lalonde, G. Lemay, and E. A. Cohen. 1997. The membrane-proximal intracytoplasmic tyrosine residue of HIV-1 envelope glycoprotein is critical for basolateral targeting of viral budding in MDCK cells. EMBO J. 16:695-705.[CrossRef][Medline]
25. Madrid, R., S. Le Maout, M. B. Barrault, K. Janvier, S. Benichou, and J. Merot. 2001. Polarized trafficking and surface expression of the AQP4 water channel are coordinated by serial and regulated interactions with different clathrin-adaptor complexes. EMBO J. 20:7008-7021.[CrossRef][Medline]
26. Matter, K. 2000. Epithelial polarity: sorting out the sorters. Curr. Biol. 10:R39-R42.[CrossRef][Medline]
27. Matter, K., W. Hunziker, and I. Mellman. 1992. Basolateral sorting of LDL receptor in MDCK cells: the cytoplasmic domain contains two tyrosine-dependent targeting determinants. Cell 71:741-753.[CrossRef][Medline]
28. Mikaelian, I., and A. Sergeant. 1992. A general and fast method to generate multiple site directed mutations. Nucleic Acids Res. 20:376.
29. Miranda, K. C., T. Khromykh, P. Christy, T. L. Le, C. J. Gottardi, A. S. Yap, J. L. Stow, and R. D. Teasdale. 2001. A dileucine motif targets E-cadherin to the basolateral cell surface in Madin-Darby canine kidney and LLC-PK1 epithelial cells. J. Biol. Chem. 276:22565-22572.
30. Mostov, K. E., M. Verges, and Y. Altschuler. 2000. Membrane traffic in polarized epithelial cells. Curr. Opin. Cell Biol. 12:483-490.[CrossRef][Medline]
31. Ohka, S., H. Ohno, K. Tohyama, and A. Nomoto. 2001. Basolateral sorting of human poliovirus receptor alpha involves an interaction with the µ1B subunit of the clathrin adaptor complex in polarized epithelial cells. Biochem. Biophys. Res. Commun. 287:941-948.[CrossRef][Medline]
32. Perego, C., C. Vanoni, A. Villa, R. Longhi, S. M. Kaech, E. Frohli, A. Hajnal, S. K. Kim, and G. Pietrini. 1999. PDZ-mediated interactions retain the epithelial GABA transporter on the basolateral surface of polarized epithelial cells. EMBO J. 18:2384-2393.[CrossRef][Medline]
33. Simmen, T., S. Honing, A. Icking, R. Tikkanen, and W. Hunziker. 2002. AP-4 binds basolateral signals and participates in basolateral sorting in epithelial MDCK cells. Nat. Cell Biol. 4:154-159.[CrossRef][Medline]
34. Simmen, T., M. Nobile, J. S. Bonifacino, and W. Hunziker. 1999. Basolateral sorting of furin in MDCK cells requires a phenylalanine-isoleucine motif together with an acidic amino acid cluster. Mol. Cell. Biol. 19:3136-3144.
35. Thomas, D. C., C. B. Brewer, and M. G. Roth. 1993. Vesicular stomatitis virus glycoprotein contains a dominant cytoplasmic basolateral sorting signal critically dependent upon a tyrosine. J. Biol. Chem. 268:3313-3320.
36. Yamamoto, T., S. Ikawa, T. Akiyama, K. Semba, N. Nomura, N. Miyajima, T. Saito, and K. Toyoshima. 1986. Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor. Nature 319:230-234.[CrossRef][Medline]
37. Yeaman, C., A. H. Le Gall, A. N. Baldwin, L. Monlauzeur, A. Le Bivic, and E. Rodriguez-Boulan. 1997. The O-glycosylated stalk domain is required for apical sorting of neurotrophin receptors in polarized MDCK cells. J. Cell Biol. 139:929-940.
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| J. Bacteriol. | J. Virol. | Eukaryot. Cell |
|---|
| Microbiol. Mol. Biol. Rev. | Clin. Vaccine Immunol. | All ASM Journals |
|---|